Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation

American Journal of Transplantation

Volumn 3, Issue 8, 2003, Pages 982-987

  Krämer, Bernhard K ^a   Zülke, Carl ^a   Kammerl, Martin C ^a   Schmidt, Christian ^a   Hengstenberg, Christian ^a   Fischereder, Michael ^a   Marienhagen, Jörg ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN A; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; ORGAN TRANSPLANTATION; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

CALCINEURIN; CORONARY ARTERIOSCLEROSIS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 0043267635     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00156.x     Document Type: Article

References (23)

1. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Report from the National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906.
2. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35 (Suppl. 1): S117-S131.
3. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217-222.
4. Cosio FG, Alamir A, Yim S et al. Patient survival after renal transplantation. I. The impact of dialysis pre-transplant. Kidney Int 1998; 53: 767-772.
5. Kasiske BL, Ramos EL, Gaston RS. The evaluation of renal transplant candidates. Clinical practice guidelines. J Am Soc Nephrol 1995; 6: 1-34.
6. Roodnat JI, Mulder PGH, Zietse R et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 1704-1710.
7. Midvedt K, Neumayer HH. Management strategies for post-transplant hypertension. Transplantation 2000; 70: SS64-SS69.
8. Fellström B. Impact and management strategies of hyperlipidemia posttransplantion. Transplantation 2000; 70: SS51-SS57.
9. Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70: SS58-SS63.
10. Jensik SC, and the FK 506 Kidney Transplant Study Group. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 1998; 30: 1216-1218.
11. Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998; 30: 1240-1242.
12. Claesson K, Mayer AD, Squifflet JP et al. Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cylosporine A patients. Transplant Proc 1998; 30: 1292-1294.
13. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368-373.
14. Ponticelli C. Calcineurin-inhibitors in renal transplantation. Too precious to be abandoned. Nephrol Dial Transplant 2000; 15: 1307-1309.
15. Margreiter R, for the European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746.
16. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Predictors of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
17. Matthews JNS, Altmann DG, Campbell MJ, Royston P. Analysis of serial measurement in medical research. Br Med J 1990; 300: 230-235.
18. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-1743.
19. Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436-443.
20. Barone G, Bunke CM, Choc MG et al. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. Transplantation 1996; 61: 968-970.
21. Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int 1998; 54: 938-944.
22. Euroaspire I, II. Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
23. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152.